We report here the in planta production of the recombinant vaccinia virus B5 antigenic domain (pB5), an attractive component of a subunit vaccine against smallpox. The antigenic domain was expressed by using efficient transient and constitutive plant expression systems and tested by various immunization routes in two animal models. Whereas oral administration in mice or the minipig with collard-derived insoluble pB5 did not generate an anti-B5 immune response, intranasal administration of soluble pB5 led to a rise of B5-specific immunoglobulins, and parenteral immunization led to a strong anti-B5 immune response in both mice and the minipig. Mice immunized i.m. with pB5 generated an antibody response that reduced virus spread in vitro and conferred protection from challenge with a lethal dose of vaccinia virus. These results indicate the feasibility of producing safe and inexpensive subunit vaccines by using plant production systems.
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plant biotechnology ͉ transgenic plants ͉ B5 glycoprotein ͉ recombinant antigen P lants have emerged as an excellent alternative to other expression systems for the production of complex pharmaceutical proteins, including recombinant subunit vaccines (1) (2) (3) (4) (5) (6) . It was shown that some plant-derived antigens can induce systemic and mucosal immune responses and, in some cases, confer protection against challenge (1) (2) (3) . Plants provide the additional advantage of direct delivery through oral or other mucosal routes (1, 6) . Despite some difficulties with the expression of certain recombinant proteins, especially those of viral origin, plant biotechnology holds the promise of producing medicinal proteins to be used in vaccine formulations.
Interest in a safe smallpox vaccine has been reawakened by the threat of bioterrorism (7, 8) and continuous outbreaks of orthopoxvirus diseases (9, 10) . A live vaccinia virus (VV)-based vaccine has been used to eventually eradicate smallpox disease (11, 12) , but does display side effects (13) . Although one approach for developing a safer vaccine is to use a highly attenuated live virus, recombinant protein-based vaccines are likely to be safer. For orthopoxviruses, there are several candidate antigens that can protect mice and nonhuman primates from lethal challenge (14) (15) (16) (17) (18) (19) (20) . The extracellular virus (EV)-specific membrane glycoprotein encoded by the B5R gene (21) (22) (23) (24) is the main target of EV-neutralizing antibodies present in human-derived vaccinia gamma globulin used to treat complications arising from smallpox vaccination (25) .
In this study, we demonstrate that the VV B5 protein can be produced in two plant expression systems. The use of the magnifection transient expression system (26) (27) (28) enabled rapid high-yield production of soluble B5 as well as selection of optimal subcellular targeting signals to use in stable plant transformation. Preparations of purified plant-derived B5 antigen (pB5) induced a strong immune response when administered parenterally and intranasally, and mice vaccinated i.m. with pB5 were protected from VV challenge.
Results
Expression Cassette Design and Cloning Strategy. The B5 glycoprotein (42 kDa) encoded by the VV (strain WR) B5R gene (21) was chosen for the production in planta of the full extracellular antigenic domain (amino acids 20-275) (Fig. 1A) , which contains the major neutralization epitopes (14, (29) (30) . Expression cassettes containing the c-Myc and His 6 tags from pIV vectors (ImpactVector, Wageningen, the Netherlands) (Fig. 1B) were subcloned into the magnICON Icon Genetics' plasmid pICH115999 (Fig. 1B) and used for empirical testing to determine the best expression in planta in conjunction with helper plasmid(s) supplying various plant intracellular signals in trans (26) (27) (28) [Icon Genetics, Halle (Saale), Germany]. This result revealed the apoplast secretion signal to be superior. Thus, the apoplast-targeting cassette from the pIV-based vector under the rbcS promoter was subcloned into the binary plant transformation vector pBIN-Plus (ImpactVector) (Fig. 1B) , generating pBIRub-apopB5 for stable tobacco transformation. The fusion of the full extracellular antigenic domain with an intracellular membrane anchor was used to generate transgenic collard plants producing insoluble pB5 in abundant vegetative biomass suitable for oral feeding (31) (Fig. 2 B and C) .
Production of B5 Protein in Plants. The magnifection system developed by Icon Genetics provided a robust and rapid method (26) (27) (28) to express recombinant pB5 in wild-type plants (Fig.  3A) . The pB5 protein was readily detected at 6-8 days postinfection in the leaf tissues transfected with the B5 and apoplasttargeting module (Fig. 3B) . The pB5 antigen remained stable in lyophilized plant tissues for several months at Ϸ100 mg/kg level when stored in air-tight containers at ambient temperatures or 4°C. Powdered material was used in a two-step affinity purification (Ni-and c-Myc Mab affinity columns) to obtain standardized pB5 samples at Ͼ50% purity ( Fig. 3 B and C) suitable for intranasal and parenteral immunization.
Stable transgenic tobacco plants expressing soluble B5 protein were generated ( Fig. 2A ) by using the pBIRub-apopB5. Several independent transgenic lines revealed the presence of pB5 by Western blotting (Fig. 2 A Right Lower) and showed no morphological abnormalities (Fig. 2 A Left) .
Transgenic collard plants expressing insoluble pB5 were generated by our method (31) by using the pB002-based binary vector (32) carrying the pB5-anchor fusion expression cassette (Fig. 1B) . Several transgenic lines revealed an antigen-specific band in leaf tissues by Western analysis (Fig. 2B Right) . The accumulation of pB5 in collard was higher when compared with transgenic tobacco expressing soluble pB5. The presence of additional amino acids at the C-terminal end (anchor) is probably responsible for the differences in migration of soluble and insoluble forms of pB5 on SDS/PAGE and the B5-specific double-banding ( Fig. 2B Right Lower) . Transgenic collard plants grew large rosettes that were Ͼ30 cm in diameter (Fig. 2B Left) and weighed Ϸ1.5 kg. Transgenic collard leaves were directly used for oral immunization in either fresh form or standardized 1-g pellets (Fig. 2C) .
Immunogenicity of pB5 Protein in Mice. Sera from mice immunized orally, intranasally, or parenterally with pB5 were tested for the presence of B5-specific antibodies by ELISA (Fig. 4) . No immune response was detected in serum of mice fed with transgenic collard plant material (fresh leaves, pellets) as well as with purified pB5 administered by gavage (Fig. 4A) . Supplementation of plant material with cholera toxin (CT) did not invoke a response, although it did result in detection of anti-CT responses present in sera (IgG) and fecal pellet extracts (IgA) (data not shown). Intranasal immunization with purified pB5 without any adjuvant did not produce antibodies in mice, although when supplemented with CT led to a distinct anti-B5 immune response (Fig. 4B) . The strongest anti-B5 immune response was detected in sera of mice immunized parenterally (Fig. 4C ). Western analysis of protein extracts from plant-and bacterially expressed B5 (Fig. 4D) confirmed the B5 specificity of the mouse serum antibodies.
Immunogenicity of pB5 Protein in the Minipig. Analysis of the immune response in the minipig revealed a response pattern similar to that observed in mice (Fig. 5) . After feeding, no anti-B5-specific antibodies were detected in the serum (Fig. 5A) , saliva, or vaginal secretions (data not shown). However, after intranasal immunization, together with CT the serum showed an increase in B5-specific IgG (Fig. 5B) . No B5-specific IgA was present in either the saliva or vaginal secretions, whereas a strong anti-CT response was detected in both the serum (IgG) and saliva (IgA). Furthermore, no anti-CT response was detected in the fecal matter or vaginal washes (data not shown). As shown in Fig. 5C , a sustained increase in B5-specific serum IgG was detected after i.m. immunization with purified pB5 in combination with CpG-ODN and alum (CpG/alum).
Protection of pB5-Vaccinated Mice Against Lethal Challenge with VV.
The level of protection in immunized mice was analyzed for the presence of B5-specific antibodies in sera by measuring the in vitro functional anti-VV activity and challenging the mice with a lethal dose of VV (Fig. 6 ). Mice were inoculated with VV once by tail scarification or three times with plant-derived B5 (in CpG/alum) i.m.; control mice were injected with extracts of total soluble protein (in CpG/alum) or left uninoculated. Three weeks after the third vaccination, sera were tested by ELISA (Fig. 6A ) and in the comet inhibition assay (Fig. 6B) as a qualitative measure of anti-EV antibody activity. We note that the serum immune response in mice was equally pronounced when using either CpG/alum or Freund's as an adjuvant (compare Figs. 6A and 4C). As shown in Fig. 6B , sera from pB5-vaccinated mice altered comet formation, whereas sera from VV-vaccinated mice inhibited comet formation completely (Left); control mouse sera did not alter comet formation (Right).
Vaccinated mice were then challenged intranasally with a lethal dose of VV and monitored daily for weight loss and morbidity (Fig. 6C) . Only the mice vaccinated with either VV or pB5 survived the challenge (Fig. 6C Lower) . Control naïve-, CpG/alum-, and nontransgenic plant material-vaccinated mice all died, indicating that survival is B5-dependent. Although 100% of the pB5-vaccinated mice survived, they did experience a greater weight loss than the VV-vaccinated mice (Fig. 6C  Upper) . Maximal weight loss of Ϸ5% was observed on day-3 postchallenge, whereas pB5-vaccinated mice underwent a loss close to 30% on day-8 postchallenge.
Discussion
Recombinant protein production is a well established technology that utilizes efficient strategies for the generation of subunit vaccines (39, 40, 41) . Recently developed plant biotechnology offers additional advantages in production scale, economy, product safety, and ways of delivery (1) (2) (3) (4) (5) (6) . At present, the main goal is to increase the overall expression yield of functional plant-derived proteins, especially those of viral origin, which sometimes seriously impair transgenic plant growth and development (42) (43) (44) .
To overcome the impediment in the case of VV B5, we used two plant expression systems. The transient system (magnifection) was used to optimize expression cassette arrangements for the antigen and expedite the production of B5 protein in a soluble form, which is more amenable for extraction and purification (45) . We note that, from several plant-specific targeting signals used to produce a soluble form of pB5, the apoplast signal led to the highest expression of recombinant protein. This information aided in efficient production of soluble pB5 in transgenic plants. The use of C-terminal tags facilitated the process of protein purification of Ͼ50% purity. Although the expression levels were lower than those obtained by magnifection, our transgenic plants are readily available for inexpensive up-scaled production.
An obvious advantage of producing recombinant medicinal proteins in plants is the possibility of oral administration (1, 6) . Considering the inevitable protein degradation in the gastrointestinal tract, the antigen must be present at higher levels so as to induce an adequate immune response. In addition, plant tissues might serve to protect subunit vaccines against digestion in the gut. To test this hypothesis, we constitutively expressed B5 in transgenic collard displaying a large vegetative biomass (31) . We confirmed the plant retaining a normal morphology, whereas insoluble antigen was expressed at high levels suitable for direct feeding experiments. We previously implemented this strategy to express rabies viral G protein in Arabidposis as a fusion protein rendering it membrane-bound and facing the cytosol (M.G., N.P., S.S., K.M., H.K, unpublished data), thus ensuring correct posttranslational modifications (especially glycosylation) and proper folding of the viral glycoproteins. The goal was to increase the likelihood of increased antigen expression of immunologically functional quality.
Mice and the minipig fed with transgenic collard and CT exhibited no detectable pB5 immune response, although a clear CT-specific IgG and IgA response was observed. This response was induced in both animal models to a lower dose of CT than the overall amount of pB5 in the feed. Moreover, no B5-specific antibody response was detected in mice immunized with soluble and purified pB5 plus CT by gavage. Because there was no response to orally administered pB5, whereas there was a response to CT, it is plausible that an antigenic protein able to induce an immune response after oral administration must naturally be taken up through the oral route (6) . Intranasal administration of a soluble plant-derived antigen, together with CT, led to a steady increase in antibody titers after each immunization in both mice and the minipig. The titers in the minipig were lower than in mice. Perhaps this outcome is due to a suboptimal dose of pB5 and/or the use of nonoptimal adjuvants. Intranasal administration of antigen leads to the appearance of IgA in stool, saliva, and vaginal secretions (46) ; however, we did not detect any. Nevertheless, a CT-specific IgA was present in the saliva of the immunized minipig and not in stool or vaginal samples.
The highest serum antibody response was found to be in parenterally immunized animals together with various adjuvants. Intramuscular vaccination of mice with purified pB5 in CpG/ alum generated an antibody response that showed in vitro and in vivo activity against VV. Sera from vaccinated animals, but not from control groups, were able to alter virus spread in the comet-inhibition assay. The greater comet-inhibition activity of sera from vaccinia-vaccinated mice, compared with that from pB5-vaccinated mice, likely reflects the reaction to multiple EV targets after VV vaccination. The pB5-immunized mice were found to be protected from lethal challenge with VV, and all mice survived the challenge. However, these mice experienced a greater weight loss compared with the VV-vaccinated mice. This result was expected given that optimal protection to the challenge is provided by a multicomponent vaccine (17, 18) . Therefore, several potent antigens are under further investigation for the development of a highly efficient, multicomponent subunit smallpox vaccine made entirely in planta. In conclusion, the efficient production of the B5 antigenic domain in planta was analyzed for its ability to induce protective immunity. The antigen was produced in soluble and insoluble forms upon transient and stable plant transformation. The soluble pB5 was purified to be used for immunization by gavage, intranasal, and parenteral routes. Transgenic collard with large edible biomass was primarily used for direct oral administration. A B5-specific response was detected after intranasal immunization, whereas the strongest response was observed after parenteral administrations. Moreover, i.m.-immunized mice generated neutralizing antibodies that inhibited the spread of VV in vitro and provided 100% protection from death after lethal challenge.
Our study presents a major step toward the efficient production of viral proteins in plants that are functionally potent and ready for use in subunit vaccine formulations to counter infectious diseases such as smallpox.
Materials and Methods
Generation of Expression Cassettes and Transformation Vectors. Plasmid pSI-80-10 (24) carrying a fragment of the VV (strain WR) genome was used to amplify the full antigenic ectodomain portion of B5 (amino acids 20-275) by using the following primers: 5Ј-CCA TGG ATT GTA CTG TAC CCA CTA TGA ATA ACG-3Ј and 5Ј-GCG GCC GCA TGA TAA GTT GCT TCT AAC GAT TCT A-3Ј. The PCR fragment was cloned (NcoI-NotI) into a group of five intermediate pIV 1 (1) (2) (3) (4) (5) vectors, thus fusing the gene to targeting signals and c-Myc tags and 6x-His 6 at C terminus (ImpactVector). As determined by transient in planta expression, the best-expression apoplast-targeting (33) cassette was subcloned (XbaI-SacI) into the stable plant transformation binary vector pBIN-Plus (ImpactVector) with kanamycin selection to generate pBIRub-apopB5.
The pB5 NcoI-SacI fragments from the corresponding pIVbased plasmids were subcloned into the carrier provector plasmid pICH11599 (magnICON) and used for vacuum infiltration of wild-type plants.
An insoluble (membrane-bound) form of pB5 protein was produced in transgenic collard plants by fusing the B5 antigenic region amplified by two consecutive rounds of PCR with primers: F, 5Ј-CTT TCA AAT ACT TCC ACC ATG GGA TGT ACT GTA CCC ACT ATG AAT AAC G-3Ј; R, 5Ј-AAG ATC CTC CTC GCT AAT AAG CTT TTG ATG ATA AGT TGC TTC TAA CGA TTC TAT TTC-3Ј; F, 5Ј-GCT CTA GAC GTT TTT ATT TTT AAT TTT CTT TCA AAT ACT TCC ACC ATG GGA-3Ј; and R, 5Ј-ATG ATA AGT TGC TTC TAA CGA TTC TAT TTC-3Ј. The fragment was cloned into a binary vector pB002 (32) expression cassette driven by CaMV-35S promoter and harboring a subcellular anchor.
For bacterial expression, the XbaI-SacI DNA fragments excised from the pIV-based constructs were subcloned into the corresponding sites of the modified pGEX3 vector (Amersham Pharmacia Biotech, Piscataway, NJ) in which the GST tag was deleted (pGEX3 ⌬⌬GST ). Resulting constructs were transformed into the Escherichia coli Rosetta-2 (DE3) strain (Novagen, Madison, WI) for expression.
Agrobacterium Infiltration of Plants Using the Magnifection System.
For rapid transient expression of recombinant B5 in planta, we used the so-called ''magnifection'' procedure [Icon Genetics, Halle (Saale), Germany] as described (26) (27) (28) , with minor modifications. GV3101 agrocultures carrying the B5 cassettes in pIV plasmids were each combined with equal volumes of cultures carrying the premanufactured helper plasmids supplying the subcellular targeting signals and recombinase-integrase complex. The mixture was diluted (1:50) in buffer [10 mM MgSO 4 , 10 mM Mes (pH 5.6), 5% sucrose, 200 M acetosyringon, and 0.02% Silwet L-77] and applied to mature Nicotiana benthamiana (Tobacco) and Beta vulgaris var. cicla (Swiss chard) plants (6-8 weeks old). Plant tissues were harvested within 7-10 days and analyzed by Western blot and ELISA.
Generation of Transgenic Plants. Tobacco (Nicotiana tabacum cv Wisconsin) leaf discs were transformed (34) with pBIRubapopB5, and Collard (Brassica oleracea cv. Morris Heading) explants were transformed by our method (31) using the pB002-based construct. Kanymycin (tobacco)-and phosphinotricin (collard)-resistant transgenic lines were selected and tested by PCR and Western blotting for the presence of pB5. Fresh collard leaves were harvested from healthy transgenic plants. Collardbased pellets were prepared by mixing lyophilized and powdered plant tissue in PBS with 0.25% (wt/vol) of cornstarch. Pellets were formed by using plastic moulds, lyophilized, and stored at 4°C in air-tight containers.
Immunological Assessment of pB5 in Mice. Six-to 8-week-old female BALB/c mice (5 or 10 mice per group) were used in all experiments. For oral immunization, each mouse was fed with 2-3 g of fresh tissue or 1 g of pellets (Ϸ100 g of antigen) over a period of 6-8 h. Control mice received wild-type plant material. In some groups plant material was supplemented with 10 g of CT (IMD Biosciences) as an adjuvant. An additional group of mice received purified pB5 (2 g) with CT by gavage. For intranasal immunization, 2 g of pB5 was administered in 10 l of saline into both nostrils; in some groups, pB5 was supplemented with CT (1 g). Mice were immunized three times at 2-week intervals. For parenteral immunization, mice were injected three times at 2-week intervals with 2 g of purified pB5. First and second immunizations were given s.c. with complete and incomplete Freund's adjuvant, respectively (Difco, Detroit, MI). The third dose was administered i.p. in saline. Blood and fecal matter were collected 10 days after each immunization. Proteins from fecal pellets were extracted in PBS (10 vol/wt) supplemented with 1% BSA and protease inhibitors as described (36) . Mice were killed 10 days after the last immunization and bled by cardiac puncture, and sera were analyzed by ELISA and Western blotting.
Immunizations for the challenge experiments were done by using CpG oligodeoxynucleotides (ODN) (sequence no. 1826: TCCATGACGT TCCTGACGT T; Coley Pharmaceutical Group, Wellesley, MA) and alum (Alhydrogel; Accurate Chemical, Westbury, NY) as an adjuvant (CpG/alum) at 50 g per mouse (38) . Mice received three i.m. vaccinations at 2-week intervals with 8 g of purified pB5, 8 g of wild-type plant total soluble protein, or CpG/alum alone. Additional control groups included naive, nonvaccinated mice and mice that were vaccinated with VV by tail scarification. Mice were bled before the third boost and 3 weeks later immediately before intranasal challenge with VV.
Immunological Assessment of pB5 in Minipig. A single 8-month-old minipig was immunized consecutively by oral, intranasal, and i.m. routes. Oral immunization consisted of two feedings with 300 g of transgenic collard leaves supplemented with 15 g of CT within 14 days. After 2 weeks, the minipig received three intranasal doses of pB5 (15 g) together with 2 g of CT (75 l per nostril in saline) at 2-week intervals. After an additional 3 weeks, the minipig received three i.m. doses of 10 g of purified pB5 supplemented with 50 g of CpG/alum. Blood, fecal matter, saliva, and vaginal secretion samples were obtained 10 days after each immunization and analyzed by ELISA and Western blotting.
Solid-Phase ELISA. The assay (37) was performed in 96-well MaxiSorp plates (Nalgen Nunc, Rochester, NY) coated overnight at 4°C with E. coli-purified B5 at 1 g/ml in PBS. Antigen-specific antibodies were detected by using the following antibodies: goat anti-mouse IgG (BD Biosciences, San Jose, CA) and anti-mouse IgA (Sigma-Aldrich) or goat anti-pig IgG/IgA (Bethyl Laboratory, Montgomery, TX). Results are given as mean Ϯ SD.
Comet Inhibition Assay. The in vitro assay was essentially performed as described in ref. 30 . Briefly, a confluent monolayer of BSC-1 cells grown in 12-well plates was infected with VV strain IHDJ at Ϸ5 pfu per well for 2 h at 37°C. The inoculum was removed and 1 ml of fresh MEM medium containing 2.5% FCS and 25 l (1:40 dilution) of pooled sera obtained from mice 3 weeks after the last boost vaccination (just before challenge) were added. Plates were incubated for Ϸ36 h at 37°C and stained with 0.2% crystal violet in 4% ethanol, and wells were photographed.
VV Challenge. Three weeks after the last protein vaccination, mice were intranasally challenged with 1.2 ϫ 10 6 pfu of VV strain WR in 20 l of sterile PBS. Mice were weighed and monitored each day. Animals that appeared morbid or had lost Ͼ30% of their initial body weight were killed in accordance with the institutional guidelines for animal welfare (38) .
